MRL Ventures Fund and Roche Fund have taken part in the intracellular drug developer's series A, which is commercialising research by Prof Dehua Pei at OSU.
Entrada Therapeutics, a US-based drug delivery platform developer based on reseach at Ohio State University (OSU), raised $59m in a series A round co-led by VC firm 5AM Ventures and healthcare investment firm MPM Capital on Tuesday. Pharmaceutical firms Merck & Co and Roche participated in the round through respective corporate venturing units Roche Fund and MRL…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
